Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,200 across all filing types
Latest filing 2026-05-19 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
关于“灵康转债”预计满足转股价格修正条件的提示性公告
Capital/Financing Update Classification · 75% confidence The document is a mandatory disclosure on the Shanghai Stock Exchange regarding the potential downward adjustment of the conversion price of the company’s outstanding convertible bonds (“灵康转债”). It outlines the terms of the bond issuance, the triggering conditions for price adjustment, procedural steps, and risk warnings. This is not reporting period financial statements or an earnings press release but rather an update on the company’s financing instrument and potential capital structure change, fitting the Capital/Financing Update category.
2026-05-19 Chinese
关于变更签字注册会计师的公告
Audit Report / Information Classification · 95% confidence The document is an announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the change of the signing certified public accountants for the company's 2025 financial audit. It details the replacement of the original signing auditors due to work adjustments and provides information about the new signing auditors, their qualifications, and independence. The document explicitly states that this change will not adversely affect the company's 2025 financial report and internal control audit work. The content focuses on audit personnel changes rather than presenting audit results or financial statements. Therefore, this is an Audit Report / Information type filing, specifically about auditor changes, not the full audit report itself.
2026-03-02 Chinese
2026年第一次临时股东会会议资料
AGM Information Classification · 95% confidence The document is titled as meeting materials for the "2026 First Extraordinary General Meeting" of Lingkang Pharmaceutical Group Co., Ltd. It includes the meeting agenda, voting procedures, and a detailed proposal regarding the change in the use of repurchased shares and the reduction of registered capital. The content is focused on the meeting itself, including legal opinions, voting instructions, and the proposal to be voted on. There is no financial statement or comprehensive financial data presented, nor is it a transcript of a call or a report publication announcement. The document is clearly the materials provided for a shareholders' meeting, specifically an Extraordinary General Meeting (EGM). According to the filing definitions, materials shared during a general meeting (AGM or EGM) fall under "AGM Information (AGM-R)". Therefore, this document is best classified as AGM Information (AGM-R). The document length is under 5,000 characters, but it contains detailed meeting materials, not just an announcement of a report, so it is not an RPA. Confidence is high given the clear meeting agenda and materials content.
2026-02-27 Chinese
关于控股股东部分股份解除质押的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the release of a portion of pledged shares by the controlling shareholder of the company. It details the number of shares released from pledge, the proportion of shares involved, and the remaining pledged shares. There is no financial report, earnings data, or management discussion. The content is about share pledge status, which relates to shareholding and capital structure changes. This fits best under Share Issue/Capital Change (SHA) as it involves changes in share pledge status, a capital-related event. The document is short and focused on this specific event, not a full report or regulatory filing.
2026-02-11 Chinese
东方金诚国际信用评估有限公司关于灵康药业集团股份有限公司2025年度业绩预亏的关注公告
Regulatory Filings Classification · 95% confidence The document is a credit rating agency's announcement regarding the credit rating and outlook of Lingkang Pharmaceutical Group Co., Ltd. It discusses the company's 2025 annual performance forecast and the reasons for expected losses, including sales declines and cost pressures. The document is an announcement of credit rating and performance concerns, not a full financial report or audit. It does not contain detailed financial statements or comprehensive management discussion. The document is relatively short (1390 characters) and serves as a notice or update rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-02-06 Chinese
关于不向下修正“灵康转债”转股价格的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the decision not to downward adjust the conversion price of its convertible bonds ('Lingkang Convertible Bonds'). It details the bond issuance, previous adjustments to the conversion price, the triggering of the downward adjustment clause, and the board's resolution not to exercise the right to adjust the conversion price downward at this time. The document is a formal disclosure about a capital/financing matter related to convertible bonds and their conversion price adjustments. It is not a full financial report, earnings release, or management discussion, but rather a specific update on financing terms and board decisions related to convertible bonds. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is under 5,000 characters and contains substantive content about financing terms, not just a report publication announcement or regulatory filing. Confidence is high due to clear focus on convertible bond terms and board resolutions on conversion price adjustments.
2026-01-30 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.